We suppose that priming of CD34+ progenitor cells by mediators which are elevated in the blood of AD patients or epigenetic effects on progenitor cells provide the basis for the increased levels of 5-LO and FLAP expression in the patient group which is not lost during the in-vitro differentiation to mast cells. Here, ALOX5AP is linked to Alzheimer disease.